-

BIOCORP: 2021 Financial Calendar

ISSOIRE, France--(BUSINESS WIRE)--Regulatory News:

BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, updates its financial reporting schedule for 2020*:

Annonce

 

Date*

2020 full-year results

 

 Thursday, April 8th, 2021

Before the market opening

Annual shareholders meeting

 

 Friday, May 7th, 2021 

2020 first-half results

 

Thursday, September 23rd, 2021

Before the market opening 

* This schedule is indicative and subject to change.

À PROPOS DE BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale since late 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 63 employees.
BIOCORP is listed on Alternext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
Follow us on Twitter @BIOCORPSystems

Contacts

BIOCORP
Jacques Gardette
Chairman of the Board

CEO
Éric Dessertenne

Sylvaine Dessard
Marketing @ Communication Director
investisseurs@biocorp.fr rp@biocorp.fr
+ 33 (0)6 88 69 72 85

ULYSSE COMMUNICATION
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26

Nicolas DANIELS
ndaniels@ulysse-communication.com
+33 (0)6 63 66 59 22

BIOCORP

BOURSE:ALCOR
Release Versions
EnglishFrench
Hashtags
#digitalhealth
#healthcare
#innovation

Contacts

BIOCORP
Jacques Gardette
Chairman of the Board

CEO
Éric Dessertenne

Sylvaine Dessard
Marketing @ Communication Director
investisseurs@biocorp.fr rp@biocorp.fr
+ 33 (0)6 88 69 72 85

ULYSSE COMMUNICATION
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26

Nicolas DANIELS
ndaniels@ulysse-communication.com
+33 (0)6 63 66 59 22

Social Media Profiles
BIOCORP on linkedin
More News From BIOCORP

BIOCORP Obtains 510(k) FDA Clearance for SoloSmart®, Sanofi’s Smart Cap for Disposable Insulin Pens

ISSOIRE, France--(BUSINESS WIRE)--Press Release BIOCORP (Paris:ALCOR), a Novo Nordisk company based in France and specialized in the design, development, and manufacturing of innovative medical devices, announced today that they have received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market SoloSmart®, Sanofi’s smart medical device that connects SoloStar® insulin pens. Eric Dessertenne, CEO of BIOCORP, said: "This approval is a major achievement for SoloSmart and ou...

BIOCORP Reports Half-year Results as of June 30, 2023

ISSOIRE, France--(BUSINESS WIRE)--Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, presents its half-year financial results as of June 30, 20231. Éric Dessertenne, CEO of BIOCORP, commented: “The first half of 2023 has been very dynamic for Biocorp with the main event being the conclusion of discussions with NOVO NORDISK, our commercial partner of the Mallya...

Completion of Novo Nordisk's Acquisition of a Controlling Stake in BIOCORP

ISSOIRE, France--(BUSINESS WIRE)--Regulatory News: Following the announcement of the planned acquisition of BIOCORP Production SA (FR0012788065 - ALCOR) (“BIOCORP”) by NOVO NORDISK (DK0060534915 - Novo-B), a leading global healthcare company headquartered in Denmark and developing treatments against diabetes and other chronic diseases (“NOVO NORDISK”), released on June 5, 2023, BIOCORP announces that, following receipt of customary regulatory approvals, NOVO NORDISK has today completed the off-...
Back to Newsroom